Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zonisamide · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Zonisamide | EXPERIMENTAL | Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited |
| Zonegran | ACTIVE_COMPARATOR | Zonegran Capsules 100 mg of EISAI INC |
| Name | Type | Description |
|---|---|---|
| Zonisamide | DRUG | Zonisamide capsules 100 mg |
| Zonegran | DRUG | Zonegran Capsules 100 mg of EISAI INC |
Inclusion Criteria: * Is the individual a healthy, normal adult man or non-child bearing potential woman who volunteers to participate? * Is s/he at least 18 years of age? * Is his/her BMI between 19 and 30, inclusive? * Is s/he considered reliable and capable of understanding his/her responsibilit...
Zonisamide is a small molecule drug being developed by Dr. Reddy's Laboratories Ltd. It is currently in Phase 1 clinical trials, but these trials are conducted in healthy volunteers, not for a specific disease. The studies are bioequivalence trials comparing Zonisamide capsules 100 mg under fasting and fed conditions.
Zonisamide is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker RDY. The company is conducting Phase 1 clinical trials for this drug, which are bioequivalence studies in healthy volunteers.
Zonisamide is in Phase 1 clinical development. There are two completed Phase 1 trials, both bioequivalence studies in healthy volunteers. The drug is investigational and not yet approved for any indication, as it is still in early-stage clinical development.
Zonisamide has two completed Phase 1 clinical trials: NCT01161966, a bioequivalence study of Zonisamide capsules 100 mg under fasting conditions, and NCT01161979, a similar study under fed conditions. Both trials enrolled 26 healthy volunteers each in the United States.
Zonisamide is a small molecule drug developed by Dr. Reddy's Laboratories Ltd. No alternative names for this drug have been mentioned in the available information. It is being studied in Phase 1 bioequivalence trials, which compare the drug's performance to a reference product.